323 related articles for article (PubMed ID: 18402849)
1. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
Zahradnik HP; Hanjalic-Beck A
Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
[TBL] [Abstract][Full Text] [Related]
3. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Schramm G; Heckes B
Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
Schramm GA; Schrah G
Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
Zahradnik HP; Goldberg J; Andreas JO
Contraception; 1998 Feb; 57(2):103-9. PubMed ID: 9589837
[TBL] [Abstract][Full Text] [Related]
6. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
7. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
Akerlund M
Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
10. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
[TBL] [Abstract][Full Text] [Related]
11. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
12. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
Winkler UH; Röhm P; Höschen K
Contraception; 2010 May; 81(5):391-400. PubMed ID: 20399945
[TBL] [Abstract][Full Text] [Related]
13. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
Nakajima ST; Archer DF; Ellman H
Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
[TBL] [Abstract][Full Text] [Related]
15. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
16. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
Anthuber S; Schramm GA; Heskamp ML
Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
[TBL] [Abstract][Full Text] [Related]
17. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Terlinden R; Uragg H; Göhler K; Kneip C
Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
[TBL] [Abstract][Full Text] [Related]
19. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
Shoupe D
Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
